title: Resource competition may lead to effective treatment of antibiotic resistant infections.
abstract: Drug resistance is a common problem in the fight against infectious diseases. Recent studies have shown conditions (which we call antiR) that select against resistant strains. However, no specific drug administration strategies based on this property exist yet. Here, we mathematically compare growth of resistant versus sensitive strains under different treatments (no drugs, antibiotic, and antiR), and show how a precisely timed combination of treatments may help defeat resistant strains. Our analysis is based on a previously developed model of infection and immunity in which a costly plasmid confers antibiotic resistance. As expected, antibiotic treatment increases the frequency of the resistant strain, while the plasmid cost causes a reduction of resistance in the absence of antibiotic selection. Our analysis suggests that this reduction occurs under competition for limited resources. Based on this model, we estimate treatment schedules that would lead to a complete elimination of both sensitive and resistant strains. In particular, we derive an analytical expression for the rate of resistance loss, and hence for the time necessary to turn a resistant infection into sensitive (tclear). This time depends on the experimentally measurable rates of pathogen division, growth and plasmid loss. Finally, we estimated tclear for a specific case, using available empirical data, and found that resistance may be lost up to 15 times faster under antiR treatment when compared to a no treatment regime. This strategy may be particularly suitable to treat chronic infection. Finally, our analysis suggests that accounting explicitly for a resistance-decaying rate may drastically change predicted outcomes in host-population models.
authors.affiliation: Bioinformatics Program, Boston University, Boston, Massachusetts, United States of America.
authors.forename: Antonio L C
authors.initials: AL
authors.lastname: Gomes
authors.affiliation: Bioinformatics Program, Boston University, Boston, Massachusetts, United States of America ; Department of Biomedical Engineering, Boston University, Boston, Massachusetts, United States of America ; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
authors.forename: James E
authors.initials: JE
authors.lastname: Galagan
authors.affiliation: Bioinformatics Program, Boston University, Boston, Massachusetts, United States of America ; Department of Biomedical Engineering, Boston University, Boston, Massachusetts, United States of America ; Department of Biology, Boston University, Boston, Massachusetts, United States of America.
authors.forename: Daniel
authors.initials: D
authors.lastname: Segrè
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004352:Drug Resistance, Microbial / Q000187:drug effects*; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents